Introduction
Chronic myelogenous leukemia (CML) is a genetic hematological malignancy that affects 1 in 100 000 people each year and is characterized by clonal expansion of transformed multipotent hematopoietic stem cells (Sawyers, 1999) . The hallmark genetic anomaly of CML is the Philadelphia chromosome (Ph þ ) that results from a reciprocal translocation between the c-abl locus on chromosome 9 and the bcr locus on chromosome 22 (Rowley, 1973; Ben-Neriah et al., 1986) . Bcr-Abl, the protein product of this translocation, is a 210 kDa chimeric tyrosine kinase that transforms fibroblasts, growth factordependent hematopoietic cell lines and primary bone marrow cells in culture (McLaughlin et al., 1987; Lugo and Witte, 1989; Ren, 2002) , and induces a myeloproliferative disorder that closely resembles CML in mice (Daley et al., 1990; Kelliher et al., 1990) .
Constitutive tyrosine kinase activity and cytoplasmic relocalization allow Bcr-Abl to activate numerous signal transduction pathways that promote cell proliferation and survival (Sattler et al., 1996) . For example, Bcr-Abl activates the Stat5 transcription factor, inducing its nuclear translocation and transcription of cell growth and survival genes, such as Cyclin-D1 and Bcl-X L (Carlesso et al., 1996; Shuai et al., 1996; de Groot et al., 2000; Gesbert and Griffin, 2000) . Bcr-Abl also activates the PI3K/Akt pathway upon phosphorylation of Tyr-177 in the Bcr region and recruitment of Grb2/Gab2 adapter proteins (Sattler et al., 1996) . PI3K is also activated by Bcr-Abl through other adapter proteins, such as Shc (Harrison-Findik et al., 1995; Raffel et al., 1996) , Crkl and c-Cbl (Sattler et al., 1996) or by direct binding of the p85 subunit of PI3K to Bcr-Abl (Skorski et al., 1997; Neshat et al., 2000) . Activation of PI3K leads to the suppression of programmed cell death through Akt and other pathways. Similarly, the Ras/Erk pathway is activated by Bcr-Abl either upon phosphorylation of Tyr-177 and direct Grb2/Sos recruitment or through the Shc adaptor protein (Goga et al., 1995; Sattler et al., 2002) . By stimulating the Ras/Erk pathway, Bcr-Abl increases growth factor-independent cell proliferation.
Members of the Src kinase family have been strongly linked to Bcr-Abl signaling and leukemogenesis (Lionberger et al., 2000; Klejman et al., 2002; Hu et al., 2004) . Bcr-Abl binds to multiple Src family members including Hck, Lyn and Fyn, leading to their activation (Danhauser-Riedl et al., 1996; Warmuth et al., 1997; Lionberger et al., 2000; Meyn et al., 2006) . Activation of SFKs may have a positive feedback effect on Bcr-Abl signaling, as SFKs directly phosphorylate Bcr-Abl on tyrosine residues critical for regulation (Pendergast et al., 1993; Warmuth et al., 1997; Million and Van Etten, 2000; Zhang et al., 2001; Smith et al., 2003; Meyn et al., 2006) . SFKs may also serve as key intermediates linking Bcr-Abl with downstream effectors. Hck has been shown to couple Bcr-Abl to Stat5 activation in myeloid leukemia cells, which may contribute to survival (Klejman et al., 2002) . Furthermore, global inhibition of SFK activity with the ATPcompetitive pyrrolo-pyrimidine A-419259 blocks Stat5 and Erk signaling, leading to growth arrest and apoptosis in CML cell lines . Here, we show for the first time that A-419259 also blocks proliferation and induces apoptosis in primary CD34 þ CML cells as well. Other studies have shown that the SFKs Hck and Lyn are overexpressed and activated in CML blast crisis patients, and upregulation correlates with disease progression and drug resistance (Dai et al., 2004; Donato et al., 2004; Wu et al., 2008) .
Consistent with the critical function of Bcr-Abl in CML, the Abl kinase inhibitor imatinib produces dramatic remission in most chronic phase CML cases (Sawyers, 1999; Kantarjian et al., 2002) . However, patients with advanced disease often acquire drug resistance and continue to progress despite imatinib therapy. In addition, residual Bcr-Abl þ primitive progenitor cells can persist in patients achieving complete cytogenetic remission (Bhatia et al., 2003) , highlighting the need for additional therapeutic targets. Given their important function in Bcr-Abl signaling and in imatinib resistance, SFKs have recently emerged as novel targets for CML treatment. However, the relative contribution of individual Src family members to BcrAbl signaling is not fully understood.
In this study, we investigated the contribution of Hck to Bcr-Abl signaling using a mutant (Hck-T338M) with engineered resistance to the broad-spectrum SFK inhibitor, A-419259. Expression of this mutant in the CML cell line, K562 and in TF-1 myeloid cells acutely transformed with Bcr-Abl allowed persistence of Hck kinase activity in the presence of A-419259 at concentrations that inhibited all endogenous Src family kinase activity. Remarkably, Hck-T338M rescued both K562 and TF-1/Bcr-Abl cells from the apoptotic effects of A-419259 treatment. This result correlated with sustained activation of Stat5 in the presence of the inhibitor and provides direct evidence that Hck alone is able to transmit antiapoptotic signals from Bcr-Abl. In addition, our data demonstrate the utility of engineered inhibitor-resistant mutants to dissect the roles of individual members of a closely related family of protein kinases in oncogenic signaling, and point to Hck as a clinically relevant target for CML therapy.
Results

Design of an inhibitor-resistant mutant of Hck
Many ATP-competitive kinase inhibitors access a hydrophobic pocket adjacent to the ATP-binding site in the kinase domain. Accessibility of inhibitors to this pocket is controlled by a nonconserved amino acid often referred to as the 'gatekeeper' residue (Liu et al., 1998) , and natural variation in the gatekeeper residue is one of the main structural determinants of inhibitor sensitivity (Eyers et al., 1998; Bishop et al., 2000; Gorre et al., 2001; Blencke et al., 2003 Blencke et al., , 2004 . Tyrosine kinases that possess a threonine at this position are sensitive to various classes of inhibitors that access the hydrophobic pocket (Table 1) . However, replacement of the gatekeeper residue with more bulky amino acids, such as methionine or isoleucine often induces resistance to these inhibitors.
To determine whether we could artificially engineer resistance to A-419259 in Hck by increasing the size of the gatekeeper residue, we examined the crystal structure of Hck in complex with a related pyrazolopyrimidine inhibitor, A-420983 (Figure 1 ). This structure revealed close contact between the gatekeeper residue (Thr-338; human c-Src crystal structure numbering (Xu et al., 1999) ) and the inhibitor, suggesting that the replacement of Thr-338 with a bulkier methionine residue would result in A-419259 resistance due to steric clash. To test this idea, wild-type Hck and Hck-T338M were expressed in Sf9 insect cells and purified to homogeneity in their downregulated conformations. Normally, Hck as well as other SFKs adopt an inactive, downregulated conformation in vivo due to the Mutations of this residue to methionine or isoleucine account for a common mechanism of resistance to inhibitors of various classes as described in the text.
Src family kinase Hck in Bcr-Abl signal transduction T Pene-Dumitrescu et al phosphorylation of a conserved tyrosine residue in the C-terminal tail (Tyr-527) by the regulatory kinases Csk and Chk (Boggon and Eck, 2004) . To attain this conformation in the recombinant kinases, while avoiding coexpression of Csk, both Hck sequences were altered at their C-terminal tails from Tyr-527-Gln-GlnGln-Pro to Tyr-527-Glu-Glu-Ile-Pro (referred to hereafter as Hck-YEEI). This modification promotes autophosphorylation of the tail independently of Csk and enhances SH2-tail interaction, stabilizing the downregulated conformation (Songyang et al., 1993; Schindler et al., 1999; Boggon and Eck, 2004) . Importantly, Hck-YEEI undergoes autophosphorylation and exhibits substrate phosphorylation kinetics similar to wild-type Hck (Porter et al., 2000; Boggon and Eck, 2004) . The sensitivity of recombinant Hck-YEEI and Hck-T338M-YEEI to A-419259 were compared in an in vitro kinase assay using a peptide substrate. As shown in Figure 2 , the T338M mutation induced dramatic resistance to A-419259, increasing the IC 50 value by almost 30-fold from 11.26 ± 1.23 nM for wild-type Hck to 315.6±80.3 nM for the T338M mutant. Kinetic analysis showed a modest difference in the K m for ATP in the T338M mutant compared to wild-type Hck (10.7 ± 2.5 mM for wild-type vs 3.9 ± 0.8 mM for T338M).
Hck-T338M retains its activity and A-419259-resistance in fibroblasts We next investigated whether the T338M mutation influenced Hck biological activity and whether resistance to A-419259 was maintained in intact cells. To address these questions, both wild-type Hck and Hck-T338M were activated by replacing the regulatory C-terminal tail tyrosine (Tyr-527) with phenylalanine (YF mutation). This mutation upregulates Hck kinase activity and induces oncogenic transformation of fibroblasts (Briggs et al., 1997; Briggs and Smithgall, 1999; Lerner and Smithgall, 2002; Lerner et al., 2005) . Rat-2 fibroblasts expressing Hck-YF, Hck-T338M-YF, Src family kinase Hck in Bcr-Abl signal transduction T Pene-Dumitrescu et al as well as wild-type Hck or the neo-resistance marker as negative controls were plated in soft agar in the presence or absence of increasing concentrations of A-419259. As shown in Figure 3a , the T338M mutation did not impair biological activity, as cells expressing Hck-YF or Hck-T338M-YF produced similar numbers of transformed colonies in the absence of the inhibitor. To determine whether transformation correlated with constitutive activation of the kinase, cell lysates were tested for reactivity with the phosphospecific antibody pY418, which recognizes the phosphotyrosine residue in the Hck activation loop (Lerner and Smithgall, 2002; Schreiner et al., 2002; Wilson et al., 2002) . Consistent with the transformation results, both Hck-YF and Hck-T338M-YF reacted strongly with this phosphospecific antibody ( Figure 3b ). Furthermore, activation loop phosphorylation correlated with phosphorylation of the endogenous Hck substrate protein, pp40 (Briggs et al., 1997; Lerner and Smithgall, 2002 ; Figure 3b ). In contrast, wild-type Hck did not exhibit kinase or transforming activity. Taken together, these results show that the T338M mutation is functionally silent and does not influence Hck biological activity in cells. Next, we investigated the sensitivity of Rat-2 cells transformed by each form of Hck to A-419259. As shown in Figure 3a , 0.3 mM A-419259 almost completely blocked colony formation by cells expressing the Hck-YF mutant. This was accompanied by complete inhibition of Hck-YF autophosphorylation and pp40 substrate phosphorylation (Figure 3b ). In contrast, the same concentration of A-419259 induced only a 25% decrease in colony formation in cells expressing Hck-T338M-YF mutant with no detectable change in kinase activity. Interestingly, the activity of Hck-T338M-YF was also unaffected by 1 mM A-419259, despite a further decrease in colony-forming activity. This finding suggests that endogenous A-419259-sensitive SFKs may cooperate with Hck to induce the transformed phenotype.
Hck-T338M expression in K562 cells confers resistance to A-419259-induced growth arrest and apoptosis The in vitro and cell-based assays described above show that the T338M mutation induces Hck resistance to A-419259 without affecting kinase activity, providing a unique probe to test the contribution of Hck to Bcr-Abl signaling in CML cells. For these studies, we first used K562 cells, a Ph þ human CML cell line in which endogenous Hck expression is not detectable by immunoblot (Figure 4 ). K562 cells were infected with recombinant retroviruses carrying wild-type Hck, the Hck-T338M mutant or a control virus carrying only the G418 selection marker. These three cell populations (K562-neo, K562-Hck and K562-Hck-T338M) were treated with A-419259, and the effect of inhibitor treatment on Hck activity was assessed with the phosphospecific antibody, pY418. As shown in Figure 4 , A-419259 caused partial inhibition of wild-type Hck at 0.1 mM and complete inhibition at 0.3 and 1.0 mM in K562-Hck cells. This observation is consistent with our previous findings that A-419259 inhibits overall SFK activity in K562 and other CML cell lines with an IC 50 value of 0.1-0.3 mM . In contrast, little change in Hck-T338M pY418 phosphorylation was observed at these A-419259 concentrations, although partial inhibition was observed at 1 mM.
Our previous work has shown that A-419259-dependent inhibition of SFK activity in K562 cells induces growth arrest and apoptosis . In addition, we found that A-419259 is 300-1000 times more potent against SFKs compared with c-Abl in vitro. To determine whether A-419259 has a direct inhibitory effect on Bcr-Abl in our experimental system, we probed the lysates from the inhibitor-treated K562 cell populations with a phosphospecific antibody against the phosphotyrosine residue in the activation loop of BcrAbl (pY412). As shown in Figure 4b , A-419259 did not inhibit Bcr-Abl phosphorylation at the autoactivation site. In contrast, the Abl-selective inhibitor imatinib caused a dose-dependent decrease of the pY412 signal (Figure 4c ). These data support the selectivity of A-419259 for SFKs vs Bcr-Abl in K562 cells, in agreement with our previous data in this cell line .
To investigate the contribution of Hck to Bcr-Ablinduced cell growth, proliferation of K562-neo, K562-Hck, and K562-Hck-T338M cells was assessed in the presence of A-419259. Figure 5 shows that 0.1 mM A-419259 induced 75-80% growth arrest of K562-Hck and K562-neo cells. Conversely, K562-Hck-T338M cells exhibited only a 50% reduction in cell proliferation at this inhibitor concentration. This result correlates with sustained Hck-T338 kinase activity compared to wildtype Hck in the presence of the inhibitor (Figure 4) . Given that 0.1-0.3 mM A-419259 completely inhibits endogenous Src family kinase activity in CML cells , this result suggests that Hck alone is able to partially sustain Bcr-Abl-induced cell proliferation (see Discussion). We next investigated whether the expression of Hck-T338M also confers resistance to A-419259-induced apoptosis in CML cells. K562-neo, K562-Hck and K562-Hck-T338M cells were treated with A-419259 for 72 h and apoptosis was measured by staining the cells with a fluorescent antiphosphatidylserine antibody and flow cytometry. As shown in Figure 6 , A-419259 induced apoptosis in K562-neo and K562-Hck cells at 0.3 and 1.0 mM. In contrast, Hck-T338M expression completely rescued K562 cells from apoptosis induced by 0.3 mM A-419259. Furthermore, K562-Hck-T338M cells also displayed significant resistance to apoptosis induced by 1 mM A-419259. These data correlate with Hck-T338M kinase activity, which is not affected by 0.3 mM and only partially inhibited by 1 mM A-419259 (Figure 4) .
Expression of Hck-T338M in K562 cells rescues the inhibitory effects of A-419259 on Stat5 and Erk activation
Previous reports suggest that Hck may couple Bcr-Abl to Stat5 and Erk activation in myeloid leukemia cells (Warmuth et al., 1997; Klejman et al., 2002) . In addition, work in our laboratory has shown that the inhibition of SFK activity in K562 cells using A-419259 induces apoptosis and growth arrest that correlates with decreased Ras/Erk and Stat5 activation . To assess the contribution of Hck to these growth and survival pathways downstream of Bcr-Abl, we determined whether Hck-T338M could rescue Ras/Erk and Stat5 activation from the inhibitory effects of A-419259. K562-neo, K562-Hck, and K562-Hck-T338M cells were treated with A-419259 and cell lysates were probed with phosphospecific antibodies for activated Erk by immunoblotting. As shown in Figure 7 , A-419259 induced a dose-dependent inhibition of Erk phosphorylation in K562-neo and K562-Hck cells. In Src family kinase Hck in Bcr-Abl signal transduction T Pene-Dumitrescu et al both cases, the phospho-Erk signal was partially reduced at 0.3 mM and completely absent at 1.0 mM. However, expression of Hck-T338M completely rescued Erk activation at 0.3 mM A-419259, and showed a partial effect at 1.0 mM. Although these data are consistent with the partial reversal of A-419259 growth arrest observed in K562-Hck-T338 cells (Figure 4) , they suggest that Hck-and Erk-independent pathways also contribute to proliferation of K562 cells.
To examine the effect of Hck-T338M on Stat5 activation, Stat5 was immunoprecipitated from lysates of A-419259-treated cells and probed with antiphosphotyrosine antibodies. As shown in Figure 8 Lysates from A-419259-treated cells in part A were immunoblotted with a phosphospecific antibody to the Abl activation loop phosphotyrosine residue (pY412; upper panels). Control blots were performed with an antibody to the Abl protein (Bcr-Abl; lower panels). (c) Inhibition of Bcr-Abl activation loop autophosphorylation by imatinib. K-562 cell populations from part A were treated with imatinib at the concentrations shown. Cell lysates were then immunoblotted with a phosphospecific antibody to the Abl activation loop phosphotyrosine residue (pY412; upper panels) as well as an antibody to the Abl protein (Bcr-Abl; lower panels).
activation. This result correlates with the levels of Hck-T338M activity observed in the presence of A-419259 ( Figure 4a ) and with the ability of Hck-T338M to rescue K562 cells from A-419259-induced apoptosis ( Figure 6 ).
Expression of Hck-T338M in Bcr-Abl-transformed TF-1 cells confers resistance to the apoptotic effects of A-419259 and correlates with sustained Stat5 activity All of the data presented thus far are derived from the K562 CML cell line. To rule out the possibility that our observations are unique to this particular system, we turned to the human myeloid cell line, TF-1 (Kitamura et al., 1989; Nakajima et al., 2001) , which requires granulocyte macrophage colony-stimulating factor (GM-CSF) for growth and survival. Expression of Bcr-Abl in TF-1 cells results in cytokine-independent survival and proliferation (Nakajima et al., 2001 ), providing a model system that lacks the secondary genetic aberrations present in K562 cells. TF-1 cells were first infected with a Bcr-Abl retrovirus, which resulted in transformation to a cytokine-independent phenotype as expected (Figure 9a ). These TF-1/Bcr-Abl cells were then infected with the wild-type and T338M-Hck retroviruses as well as the control virus carrying only the drug selection marker. Expression of these Hck proteins did not significantly affect the cytokineindependent growth of these cells (Figure 9a ). We also expressed the Hck proteins alone in TF-1 cells, and observed that they were unable to stimulate GM-CSF-independent proliferation on their own (Figure 9a) . All of the cell lines grew in the presence of GM-CSF (data not shown).
Next, we examined the effect of A-419259 treatment on survival of TF-1/Bcr-Abl cells. As shown in Figure 9b , incubation of the TF-1/Bcr-Abl vector control cells with A-419259-induced apoptosis in a dose-dependent manner. Expression of wild-type Hck partially reversed apoptosis in response to 0.3 and 1 mM A-419259 in the TF-1/Bcr-Abl population. However, TF-1/Bcr-Abl/Hck-T338M cells were much more resistant to A-419259-induced apoptosis, with almost complete protection at 0.3 mM. This effect closely parallels that observed in K-562 cells expressing Hck-T338M ( Figure 6 ). Note that parental TF-1 cells are completely unresponsive to A-419259 in this assay .
We next assessed Hck and Stat5 activity in each TF-1/ Bcr-Abl cell population following A-419259 treatment. As shown in Figure 9c , wild-type Hck activity was partially inhibited with 0.1 and 0.3 mM A-419259 and completely blocked at 1 mM. Conversely, Hck-T338M showed significant resistance to A-419259, with partial inhibition observed only at 1 mM A-419259. Expression 
A-419259 inhibits proliferation and induces apoptosis in CML CD34
þ progenitor cells In a final series of experiments, we determined whether selective inhibition of SFK activity affects the growth and survival of primary CML cells. Purified CD34 þ progenitors from three chronic phase CML patients were incubated with A-419259 in the presence of cytokines (see Supplementary materials and methods for details). A-419259 treatment induced a dose-dependent inhibition of cell proliferation in all three patient samples, with caspase activation evident as early as 16 h (Figure 10 ). The extent of growth inhibition and caspase activation is comparable to that observed with 1 mM imatinib treatment. These results provide the first evidence that inhibition of SFK activity is sufficient to induce cell-cycle arrest and apoptosis in primary CD34 þ CML cells. 
Discussion
Src family kinases have been implicated as important therapeutic targets for the treatment of CML (Kantarjian et al., 2007) with the success of dual Abl/ Src inhibitors, such as dasatinib (Martinelli et al., 2005; Olivieri and Manzione, 2007) . However, dasatinib has a broad range of molecular targets that include not only Bcr-Abl and the SFKs Fgr, Fyn, Hck, Lck, Lyn and Yes (Das et al., 2006) , but also c-Kit, the PDGF receptor and the Ephrin receptor tyrosine kinase (Melnick et al., 2006) . Although target promiscuity may be critical to the efficacy of many approved drugs, this property has traditionally been regarded as undesirable due to possible adverse effects. This concept points to a need for drugs that have 'controlled promiscuity'-ones that specifically inhibit only disease-relevant targets. In the case of CML, one key to effective progress in designing such drugs is a more in-depth understanding of the relative contribution of individual members of the Src kinase family to Bcr-Abl signaling. Work presented here provides a novel approach to dissect the individual roles of myeloid Src family kinases to Bcr-Abl signaling and provides new evidence supporting a unique role for Hck in Bcr-Abl-induced proliferation and survival. þ cells from three chronic phase CML patients were plated in triplicate in 96-well plates at 10 5 cells/ml and incubated for 16 or 48 h in the presence of A-419259 or imatinib at the concentrations indicated. Cell proliferation was monitored using the CellTiter-Blue viability assay as described in 'Materials and methods'. The average fold increase in the relative number of cells from three replicate assays is shown ± s.d. (left panels). Apoptosis was measured in each well using the Apo-One Caspase-3/-7 assay as described in 'Materials and methods'. The average fold increase in caspase-3/-7 signal intensity from three replicate wells is shown±s.d. (right panels).
Src family kinase Hck in Bcr-Abl signal transduction T Pene-Dumitrescu et al
In this study, we exploited engineered inhibitor resistance to elucidate the role of Hck in Bcr-Abl signaling. Inhibition of protein kinases by ATP-competitive compounds often depends on the presence of a relatively small threonine residue at the gatekeeper position adjacent to the hydrophobic pocket in the catalytic site. Substitution of the gatekeeper residue with amino acids bearing bulkier side chains can dramatically reduce inhibitor potency (Table 1) . Some of the first drugs developed against protein-tyrosine kinases include imatinib, which inhibits Abl, c-Kit and the PDGFR, as well as and gefitinib and erlotinib, which target the EGF receptor. Each of these compounds targets the hydrophobic pocket, and clinical resistance to these inhibitors can arise from mutations that replace the gatekeeper residue with bulkier amino acids (Blencke et al., 2004) . On the basis of these observations, we engineered an A-419259-resistant Hck allele by replacing its gatekeeper residue, Thr-338, with methionine. This mutant allowed us to test the hypothesis that the expression of inhibitorresistant Hck alone is sufficient to rescue CML cells from the antiproliferative and apoptotic effects of this broad-spectrum SFK inhibitor .
Using both in vitro and cellular model systems, we first provide proof-of-principle evidence that the T338M mutation renders Hck resistant to A-419259. Thus, Hck-T338M was 30-fold less sensitive to A-419259 than wildtype Hck in an in vitro kinase assay (Figure 2 ). In addition, the expression of active forms of wild-type Hck or the Hck-T338M mutant in Rat-2 fibroblasts induced similar levels of transformation, suggesting that T338M mutation does not significantly affect the biological function of Hck in a cell-based system (Figure 3a) . The Hck-T338M-YF mutant was at least 10-fold less sensitive to A-419259 than Hck-YF in the fibroblast transformation assay (Figure 3 ). More importantly, we show that Hck-T338M also maintains resistance to A-419259 upon expression in K562 cells and Bcr-Abl-transformed TF-1 cells, allowing us to test the individual contribution of Hck to Bcr-Abl transformation (Figures 4 and 9) . The Hck-T338M mutation did induce a subtle decrease in the K m for ATP relative to the wild-type kinase in vitro. Although this difference did not appear to impact the biological functions of Hck examined here, this observation represents a possible caveat of the engineered inhibitor-resistant mutant approach.
Previous experiments with selective inhibitors as well as an Hck dominant-negative mutant suggest that SFKs contribute to Bcr-Abl-induced cell proliferation (Warmuth et al., 1997; Abram and Courtneidge, 2000; Lionberger et al., 2000; Wilson et al., 2002) . A-419259 treatment also led to the suppression of Erk activity, a critical component of proliferative signaling downstream of Bcr-Abl (Hoover et al., 2001; Wilson et al., 2002) . In this study, we show that Hck-T338M expression has a moderate protective effect on the A-419259-induced inhibition of cell proliferation ( Figure 5 ), and this effect correlated with a rescue of Erk activity (Figure 7) . The observation that Hck-T338M does not fully reverse A-419259-induced growth arrest and Erk inhibition suggests that other pathways contribute to Bcr-Abl-mediated cell proliferation.
Previous work in our laboratory has shown that collective SFK inhibition in K562 cells using A-419259 induces apoptosis that correlates with decreased Stat5 activation . Here, we show that Hck-T338M, but not wild-type Hck, fully protects K562 cells against the apoptotic effects of 0.3 mM A-419259 ( Figure 6 ). This new finding supports a nonredundant role for Hck in Bcr-Abl survival signaling in CML cells. In addition, Hck-T338M expression rescued Stat5 activation, which is completely blocked by A-419259 in control cells as well as cells expressing wild-type Hck (Figure 8) . These results identify Hck as an important target for the development of apoptosis-inducing drugs for the treatment of CML. However, our data do not exclude the possibility that additional Src family members may participate in Bcr-Abl antiapoptotic signaling in other experimental systems. For example, siRNA against Lyn induces apoptosis of CML blast crisis cells, especially of lymphoid origin (Ptasznik et al., 2004) . Furthermore, Lyn overexpression has been identified as an alternative mechanism of imatinib resistance in the absence of Bcr-Abl mutations (Dai et al., 2004; Wu et al., 2008) . Taken together, these findings suggest that differences may exist in the roles of various SFKs within different hematopoietic lineages transformed by Bcr-Abl.
There is increasing evidence that patients achieving complete cytogenetic remission on imatinib have persistent residual CML stem cells (nonproliferating CD34 þ cells), which might be responsible for relapse upon imatinib cessation (Cortes et al., 2004; Mauro et al., 2004; Holtz et al., 2005) . These quiescent CD34 þ cells represent less than 1% of total CD34 þ cells (Copland et al., 2006) . Here, we show for the first time that selective inhibition of SFK activity by A-419259 blocks proliferation and induces apoptosis in primary CML CD34 þ progenitor cell populations as effectively as imatinib. This observation suggests that SFKs have a major function in Bcr-Abl signaling in primary CML progenitors. Future work will address the effect of selective SFK inhibition on the nonproliferating CD34 þ cell population.
By pairing an inhibitor-resistant SFK mutant with a broad-spectrum SFK inhibitor, we have established new pharmacological evidence for Hck in Bcr-Abl survival signaling. This work validates Hck as a specific target for anti-CML drugs. More generally, our studies demonstrate the utility of mutants with engineered inhibitor resistance to address the contributions of individual members of a highly homologous kinase family to specific signaling pathways.
Materials and methods
Cell culture K562, TF-1 and Rat-2 cells were obtained from the American Type Culture Collection and cultured as described elsewhere (Lerner and Smithgall, 2002; Wilson et al., 2002) . Primary
CD34
þ CML cells were isolated using an immunomagnetic column separation method (Miltenyi Biotech, Auburn, CA, USA) following the manufacturer's instructions.
Hck protein purification and kinase assay Human Hck-YEEI and Hck-T338M-YEEI were expressed in Sf9 insect cells and purified as described by Schindler et al. (1999) and Trible et al. (2006) . Kinase assays were performed using the Z'-Lyte method according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA) and our published protocols (Trible et al., 2006) .
Rat-2 fibroblast transformation assay
Active forms of Hck and Hck-T338M were expressed in Rat-2 fibroblasts and transformation was assessed as colony formation in soft agar (Briggs and Smithgall, 1999; Schreiner et al., 2002) . Hck expression and autophosphorylation were assessed by immuoblotting of clarified cell protein extracts.
Retroviral transduction of leukemia cell lines
Wild type and T338M mutant forms of Hck were expressed in K562 CML cells using the retroviral expression vector pMSCV-IRES-neo (Clontech, Mountain View, CA, USA). Transformation of TF-1 cells with a Bcr-Abl retrovirus carrying a G418 resistance marker is described elsewhere (Meyn et al., 2006) . These cells were then infected with retroviruses carrying the wild type and T338M forms of Hck and a second antibiotic selection marker (puromycin resistance). Hck was immunoprecipitated from transduced cell lysates and immunoblotted for Hck protein and activation loop auotphosphorylation. Activation of the Stat5 and Erk pathways was evaluated with phosphospecific antibodies as described by Wilson et al. (2002) .
Proliferation and apoptosis assays Proliferation was assessed using the CellTiter-Blue Cell viability assay (Promega, Madison, WI, USA) and the manufacturer's protocol. Apoptosis was measured using an antiphosphatidylserine antibody conjugated to Alexa Fluor 488 (Millipore, Billerica, MA, USA), and flow cytometry. Caspase activation was measured using the Apo-One Caspase-3/-7 assay (Promega) and the manufacturer's instructions (Supplementary information).
